Skip to main content
. 2020 Jan 30;13(2):22. doi: 10.3390/ph13020022

Figure 2.

Figure 2

(A) Structure of Glu-C(O)-Lys(Ahx-HBED-CC) (PSMA-11) for labelling with gallium-68 and PSMA-617 for labelling with, e.g., gallium-68 and lutetium-177. (B) 68Ga-PSMA-11 PET at baseline and (C) after 2 cycles of [177Lu]Lu-PSMA-617 therapy demonstrating considerable reduction of PSMA-expressing metastases in lymph nodes and bone (adapted from Fendler et al., originally published in J Nucl Med [183]).